The Regional Center Vienna

Boehringer Ingelheim opened Vienna, its first international site, in 1948. Ever since its foundation, this site has seen continuous growth and is now run by the RCV, a regional affiliate of Boehringer Ingelheim, which is responsible for over 30 countries in Central and Eastern Europe and Central Asia. In total, more than 3,080 employees work for Boehringer Ingelheim in Vienna.

The Vienna site serves as the global company hub for cancer research. This includes the areas of oncology and immune modulation as well as research for NBE (New Biological Entities). On top of that, the company’s approach towards the exploration of new emerging scientific and technological ideas is executed in the ‘Research Beyond Borders’ initiative across the entire research spectrum.

Another important area for Boehringer Ingelheim in Vienna is the development and production of biopharmaceuticals. The focus is on recombinant therapeutic proteins and plasmid DNA from microorganisms, as well as biopharmaceuticals from cell-culture. In addition to this in-house biopharmaceutical production, contract manufacturing has also been conducted in Vienna since 1995.

In order to further boost its biopharmaceutical production portfolio, the company opened the so-called Large-Scale Cell Culture (LSCC) facility in Vienna in October 2021. This is an essential addition to the Boehringer Ingelheim’s global biopharmaceutical manufacturing network as it adds a total capacity of 185,000 liters with flexible production volume. This multi-product facility is one of the most advanced of its kind, ensuring a high degree of automation and digitalization through smart technologies and artificial intelligence applications.